The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. The treatment of cancer has shifted away from mass market blockbuster cytotoxic drugs toward a more personalized therapy approach. However, government austerity packages could see slower commercial growth and larger generic erosion of key brands.
Features and benefits
Report Details:
Published: September 2012
No. of Pages: 157
Price:Single User License:US$11400 Corporate User License:US$28500
Highlights
Targeted therapies comprise 60% of the top 20 brands in 2011 with Roche’s monoclonal antibody franchise maintaining the top three positions. A potential to demonstrate improved clinical efficacy with reduced off-target toxicity, combined with an ability to demand higher prices, makes this drug class clinically and commercially attractive.
An aging cytotoxic market means that cytotoxic brands are becoming less commercially attractive. In the past few years many of the blockbuster cytotoxics have come off-patent and now face generic erosion. As developers turn their attention toward new targeted therapies the number of new cytotoxics entering the market has decreased.
Antihormonal therapies have high clinical attractiveness, but despite strong sales they are limited to two indications. Effective lifecycle management has ensured that sales remain high despite patent expiries in almost every major market.
Your key questions answered
Features and benefits
- Assess detailed drug information for the leading oncology brands, including detailed clinical trial information for each approved indication
- Understand the key factors that led to the success of the top 20 oncology therapy brands and the obstacles that they have encountered
- Gain insight into the clinical and commercial attractiveness for each of the branded drugs and how this will affect their future sales
Report Details:
Published: September 2012
No. of Pages: 157
Price:Single User License:US$11400 Corporate User License:US$28500
Highlights
Targeted therapies comprise 60% of the top 20 brands in 2011 with Roche’s monoclonal antibody franchise maintaining the top three positions. A potential to demonstrate improved clinical efficacy with reduced off-target toxicity, combined with an ability to demand higher prices, makes this drug class clinically and commercially attractive.
An aging cytotoxic market means that cytotoxic brands are becoming less commercially attractive. In the past few years many of the blockbuster cytotoxics have come off-patent and now face generic erosion. As developers turn their attention toward new targeted therapies the number of new cytotoxics entering the market has decreased.
Antihormonal therapies have high clinical attractiveness, but despite strong sales they are limited to two indications. Effective lifecycle management has ensured that sales remain high despite patent expiries in almost every major market.
Your key questions answered
- Product profiles and development overviews detailing companies involved and the key clinical data leading to each approval
- Overview of brand positioning in marketed indications relative to competitors and in terms of ability to meet unmet needs
- SWOT analysis of each brand in the seven major market top 20
- In depth assessment of each brand’s clinical and commercial attractiveness, including Datamonitor’s drug assessment charts
